Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer - A Norwegian Population Based Observational Study (NORPACT-2)

NCT04423731 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT04423731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04423731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer - A Norwegian Population Based Observational Study (NORPACT-2)
Lead sponsor
Oslo University Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2018
Completion date
December 31, 2025
Enrollment
251 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic adenocarcinoma, chemotherapy effect, locally advanced pancreatic adenocarcinoma, pancreatectomy